Recruiting Ankylosing Spondylitis Studies in Montreal
Fibrosis Lessens After Metabolic Surgery
Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), a major global public health concern, is commonly associated with obesity...
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants ...
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cance...
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
In the phase I part, to determine the recommended doses (RD) and dosing regimens of \[177Lu\]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive...
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD....
An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease
Fosigotifator is an investigational drug being researched for the treatment of Vanishing White Matter disease in adult, pediatric and infant participants. This is a 201-week, open-label, multiple coho...
About Ankylosing Spondylitis Clinical Trials in Montreal
Ankylosing spondylitis is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, causing pain, stiffness, and potentially spinal fusion. It typically begins in early adulthood. Treatment includes NSAIDs, biologics (TNF and IL-17 inhibitors), and physical therapy.
There are currently 6 ankylosing spondylitis clinical trials recruiting participants in Montreal, QUEBEC. These studies are seeking a combined 465 participants. Research is being sponsored by Ali Aminian, AstraZeneca, Merck Sharp & Dohme LLC and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.
Ankylosing Spondylitis Clinical Trials in Montreal — FAQ
Are there ankylosing spondylitis clinical trials in Montreal?
Yes, there are 6 ankylosing spondylitis clinical trials currently recruiting in Montreal, QUEBEC. Browse the studies on this page to find one that fits.
How do I join a clinical trial in Montreal?
Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Montreal research site will contact you about next steps.
Are clinical trials in Montreal free?
Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Montreal studies also compensate for your time and travel.
What ankylosing spondylitis treatments are being tested?
The 6 active trials in Montreal are testing new therapies including novel drugs, biologics, and treatment approaches for ankylosing spondylitis.
Data updated March 2, 2026 from ClinicalTrials.gov